BioPharmSignal logoBioPharmSignal

Biotech News

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.Company update

The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. BETHLEHEM, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and

Related news

OSUROraSure Technologies, Inc.2026-01-05 13:00 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

BJDXBluejay Diagnostics2026-03-12 10:30 EST

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

BIAFbioAffinity Technologies, Inc.2026-08-07 12:00 EST

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-04-28 13:16 EST

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

BRLIBio-Reference Laboratories2026-07-27 20:05 EST

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

BJDXBluejay Diagnostics2026-01-27 13:00 EST

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all latest news

OraSure Technologies, Inc.

Decentralized Diagnostics OraSure Technologies develops point-of-need and at-home diagnostic tests intended to make testing more accessible, private and convenient. Rapid-Test Portfolio The company's products cover infectious diseases and other conditions across consumer, clinical, public-health and community settings. Subsidiaries...

Recent company news

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OSUROraSure Technologies, Inc.2026-07-21 20:30 EST

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-05-06 20:05 EST

OraSure Announces First Quarter 2026 Financial Results

Stock data

Close
4.00 USD
Market cap
275.39M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States